Credit Suisse’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-130,424
| Closed | -$1.46M | – | 4374 |
|
|
2017
Q3 | $1.46M | Sell |
130,424
-149,917
| -53% | -$1.65M | ﹤0.01% | 2812 |
|
|
2017
Q2 | $3.08M | Buy |
280,341
+98,595
| +54% | +$986K | ﹤0.01% | 1936 |
|
|
2017
Q1 | $1.78M | Sell |
181,746
-15,172
| -8% | -$152K | ﹤0.01% | 2431 |
|
|
2016
Q4 | $2.13M | Buy |
196,918
+139,586
| +243% | +$1.4M | ﹤0.01% | 2395 |
|
|
2016
Q3 | $588K | Sell |
57,332
-59,823
| -51% | -$652K | ﹤0.01% | 3335 |
|
|
2016
Q2 | $1.53M | Sell |
117,155
-186,522
| -61% | -$2.44M | ﹤0.01% | 2556 |
|
|
2016
Q1 | $3.34M | Buy |
303,677
+243,236
| +402% | +$2.16M | ﹤0.01% | 1809 |
|
|
2015
Q4 | $556K | Buy |
60,441
+29,901
| +98% | +$250K | ﹤0.01% | 3296 |
|
|
2015
Q3 | $212K | Sell |
30,540
-156,200
| -84% | -$1.34M | ﹤0.01% | 3903 |
|
|
2015
Q2 | $1.83M | Buy |
186,740
+43,849
| +31% | +$399K | ﹤0.01% | 2620 |
|
|
2015
Q1 | $1.27M | Sell |
142,891
-27,012
| -16% | -$215K | ﹤0.01% | 2779 |
|
|
2014
Q4 | $1.49M | Buy |
169,903
+77,546
| +84% | +$628K | ﹤0.01% | 2802 |
|
|
2014
Q3 | $636K | Buy |
92,357
+13,246
| +17% | +$79.4K | ﹤0.01% | 3448 |
|
|
2014
Q2 | $417K | Sell |
79,111
-26,841
| -25% | -$131K | ﹤0.01% | 3934 |
|
|
2014
Q1 | $482K | Sell |
105,952
-4,748
| -4% | -$22.9K | ﹤0.01% | 3738 |
|
|
2013
Q4 | $558K | Sell |
110,700
-34,587
| -24% | -$166K | ﹤0.01% | 3701 |
|
|
2013
Q3 | $737K | Buy |
145,287
+92,415
| +175% | +$515K | ﹤0.01% | 3200 |
|
|
2013
Q2 | $262K | Buy |
+52,872
| New | +$252K | ﹤0.01% | 3707 |
|
Credit Suisse's SCLN Position: Q4 2017 in Review
Credit Suisse sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 130,424 shares — an estimated $1.46M sold.
Credit Suisse first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $3.34M in Q1 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Credit Suisse reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Credit Suisse sold 130,424 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.46M.
- Credit Suisse first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Credit Suisse's Sciclone Pharmaceuticals Inc position peaked at $3.34M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Credit Suisse's 13F filing for Q4 2017, filed 14 Feb 2018.